Park J, et al. - In view of the prior encouraging results seen with the 2-week schedule of hypofractionated radiotherapy as a salvage treatment for hepatocellular carcinoma (HCC), experts evaluated its long-term clinical outcomes in patients with recurrent HCC ineligible for curative treatments. They retrospectively enrolled 77 patients (84 lesions) with HCC who were given hypofractionated radiotherapy between December 2008 and July 2013 and administered 3.5–5 Gy/fraction for 2 weeks, resulting in a total dose of 35–50 Gy. Good local control and satisfactory treatment-related toxicity during the long-term follow-up period were seen with the 2-week schedule of hypofractionated radiotherapy for recurrent HCC. For recurrent HCC, especially tumors near a radiosensitive gastrointestinal organ, this fractionation schedule can be a potential salvage treatment option.